Otonomy to Present at the J.P. Morgan Healthcare Conference
January 04, 2018 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for diseases and disorders of the ear,...
Otonomy Announces Plan to Focus Resources on Development Programs
November 27, 2017 16:30 ET
|
Otonomy, Inc.
Company to focus resources on completing OTIVIDEX™ clinical development to support U.S. regulatory approval for Ménière’s disease, and advancing multiple other programs addressing hearing loss and...
Otonomy to Present at Piper Jaffray Healthcare Conference
November 22, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 22, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update
November 08, 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX™ in Patients with Ménière's Disease
November 08, 2017 16:05 ET
|
Otonomy, Inc.
Achieved primary endpoint (p value = 0.029)Company plans to meet with FDA to discuss results and clinical requirements for registrationManagement will review results during third quarter conference...
Otonomy to Report Third Quarter 2017 Financial Results and Provide Corporate Update
November 01, 2017 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy Provides Business and Financial Update
September 13, 2017 07:30 ET
|
Otonomy, Inc.
Actions taken to reduce costs following suspension of OTIVIDEX™ developmentNon-commercial workforce reduced by one-thirdCurrent cash balance expected to fund company into 2020Review underway to...
Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
August 30, 2017 07:00 ET
|
Otonomy, Inc.
Missed primary endpoint (p value = 0.62) and all key vertigo secondary endpointsCompany to immediately suspend all development activities for OTIVIDEXCompany is also undertaking a review of its...
Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update
August 03, 2017 16:12 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 03, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...
Otonomy to Report Second Quarter 2017 Financial Results and Provide Corporate Update
July 27, 2017 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 27, 2017 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases and...